Download PDF
Exp Clin Endocrinol Diabetes 2008; 116(8): 481-486
DOI: 10.1055/s-2008-1058085
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Increased Low Grade Inflammatory Serum Markers in Patients with Polycystic Ovary Syndrome (PCOS) and their Relationship to PPARγ Gene Variants

B. Knebel 1 , O. E. Janssen 2 , S. Hahn 3 , S. Jacob 1 , J. Gleich 1 , J. Kotzka 1 , D. Muller-Wieland 4
  • 1Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Germany
  • 2Endokrinologikum Hamburg, Hamburg, Germany
  • 3Praxis für Endokrinologie, Wüppertal, Germany
  • 4Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Clinic St. Georg, Hamburg, Germany
Further Information

Publication History

received 17.10.2007 first decision 19.12.2007

accepted 11.02.2008

Publication Date:
25 March 2008 (online)

Also available at
    Permissions and Reprints

Abstract

The Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in premenopausal women and is associated with features of the insulin resistance syndrome, altered glucose homeostasis, and central obesity. Inflammation appears to be a link between obesity and insulin resistance, because adipose tissue is one major source of proinflammatory cytokines. Since peroxisome proliferator-activated receptor (PPAR)γ affects adipocyte differentiation as well as insulin sensitivity, we investigated whether the levels of proinflammatory factors in PCOS patients are related to sequence variations of the PPARγ gene. Proinflammatory cytokine levels, i.e. IL-1β, IL-6, IL-7, IL-8, IL-17 and TNFα, were evaluated in PCOS patients (n=21) in comparison to obese controls (n=120). Next to this the complete coding sequence of the PPARγ gene was investigated by resequencing all probands. We show that the levels of IL-8 and IL-17 were unchanged, IL-1β, IL-6 and TNFα were elevated and the level of IL-7 was decreased in PCOS patients compared to obese controls. Sequence analyses of the PPARγ gene indicated that neither the common polymorphisms P12A or H478 H, nor novel polymorphisms (E79Q, V32G, -39 T>C, c.480 +33 t>g,) or unique sequence variations (S22S, A23A, T41A, S226C, K272 T, I484I, c.819 +24 a>c) detected in this investigation revealed evidence for a direct association of PPARγ with altered IL-7, IL-1β, IL-6 and TNFα levels in PCOS patients. So, alterations in inflammatory serum markers appear to be a feature of PCOS per se, and are independent of PPARγ variants.

Key words

PPARγ - PCOS - insulin resistance - metabolic syndrome - inflammation

References

  • 1 Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes.  Recent Prog Horm Res. 2001;  56 295-308
    CrossrefPubMedGoogle Scholar
  • 2 Salesi M, Bravo-Vera R, Sheikh A, Gouller A, Poretzky L. Pathogenesis of the polycystic ovary syndrome: What is the role of obesity?.  Metabolism. 2004;  53 358-376
    CrossrefPubMedGoogle Scholar
  • 3 O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in beta-cell function in functional ovarian hyperandrogenism.  J Clin Endocrinol Metab. 1993;  76 1241-1247
    CrossrefPubMedGoogle Scholar
  • 4 Ehrmann DA. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
    CrossrefPubMedGoogle Scholar
  • 5 Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome.  Hum Reprod. 1999;  16 1255-1260
    PubMedGoogle Scholar
  • 6 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism.  Endocrine Rev. 1999;  20 649-688
    CrossrefPubMedGoogle Scholar
  • 7 Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene.  Biochem Biophys Res Commun. 1997;  233 756-759
    CrossrefPubMedGoogle Scholar
  • 8 Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis.  Genes Dev. 2000;  14 1293-1307
    PubMedGoogle Scholar
  • 9 Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.  J Clin Invest. 2000;  106 467-472
    CrossrefPubMedGoogle Scholar
  • 10 Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism.  Diabetes. 2002;  51 2341-2347
    PubMedGoogle Scholar
  • 11 Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary sindrome with the Pro12Ala polymorphism in the PPARγ gene.  J Clin Endocrinol & Metab. 2002;  87 772-775
    CrossrefPubMedGoogle Scholar
  • 12 Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, Tapanainen JS, Laakso M. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.  Hum Reprod. 2003;  18 540-543
    CrossrefPubMedGoogle Scholar
  • 13 Ori F, Matarese G, Biase S Di, Palomba S, Labella D, Sanna V, Savastano S, Zullo F, Colao A, Lombardi G. Exon 6 and 2 peroxisome proliferator-activated receptorγ polymorphisms in polycystic ovary sindrome.  J Clin Endocrinol & Metab. 2003;  88 5887-5892
    PubMedGoogle Scholar
  • 14 Altshuler D, Hirschhorn JN, Klannemark M, Lindgreen CM, Vohl MC, Nemesh J, Lane CR, Schaffer SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.  Nat Genet. 2000;  26 76-80
    CrossrefPubMedGoogle Scholar
  • 15 Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARγamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.  Nat Genet. 1998;  20 284-287
    CrossrefPubMedGoogle Scholar
  • 16 Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deep SS, Auwerx J, Uusitupa M, Laasko M. Two polymorphisms in the peroxisome proliferators-activated receptor-gamma gene are associated with severe overweigt among obese women.  J Clin Endocrinol Metab. 1999;  84 3708-3712
    CrossrefPubMedGoogle Scholar
  • 17 Schaffler A, Barth N, Schmitz G, Zieht B, Palitzsch KD, Scholmerich J. Frequency and significance of Pro12 Ala and Pro115Gln polymorphisms in gene for peroxisome proliferation-activated receptor –gamma regarding metabolic parameters in a Caucasian cohort.  Endocrine. 2001;  14 369-373
    CrossrefPubMedGoogle Scholar
  • 18 Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians.  Diabetologia. 2001;  44 1170-1176
    CrossrefPubMedGoogle Scholar
  • 19 Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Haring HU. The PPARγamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients.  Horm Metab Res. 2000;  32 413-416
    PubMedGoogle Scholar
  • 20 Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes.  Diabetes. 1999;  48 1466-1468
    PubMedGoogle Scholar
  • 21 Semple RK, Chatterjee VK, O'rahilly S. PPARgamma and human metabolic disease.  J Clin Invest. 2006;  116 581-589
    CrossrefPubMedGoogle Scholar
  • 22 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ.  J Clin Endocrinol Metab. 2004;  89 2548-2556
    CrossrefPubMedGoogle Scholar
  • 23 Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control.  J Endocrinol. 2001;  169 453-459
    CrossrefPubMedGoogle Scholar
  • 24 Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation.  Cytokine Growth Factor Rev. 2002;  13 413-421
    CrossrefPubMedGoogle Scholar
  • 25 Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.  Metabolism. 1999;  48 437-441
    CrossrefPubMedGoogle Scholar
  • 26 Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 2453-2455
    CrossrefPubMedGoogle Scholar
  • 27 Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.  Diabetologia. 2003;  46 625-633
    PubMedGoogle Scholar
  • 28 Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation.  Eur J Endocrinol. 2004;  150 525-532
    CrossrefPubMedGoogle Scholar
  • 29 Puder JJ, Varga S, Kraenzlin M, Geyter C De, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.  J Clin Endocrinol Metab. 2005;  90 6014-6021
    CrossrefPubMedGoogle Scholar
  • 30 Yao Q, Nordfors L, Axelsson J, Heimburger O, Qureshi AR, Barany P, Lindholm B, Lonnqvist F, Schalling M, Stenvinkel P. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy.  Atherosclerosis. 2005;  182 105-111
    PubMedGoogle Scholar
  • 31 Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Muller-Wieland D, Mann K, Janssen OE. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome.  Clin Endocrinol. 2005;  62 573-579
    CrossrefPubMedGoogle Scholar
  • 32 Jovanovic DV, Battista JA Di, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.  J Immunol. 1998;  160 3513-3521
    PubMedGoogle Scholar
  • 33 Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick LB. Cytokine response to diabetic ketoacidosis and its treatment.  Clin Immunol. 2003;  108 175-181
    CrossrefPubMedGoogle Scholar
  • 34 Zozulinska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients.  Diabetologia. 1999;  42 117-118
    CrossrefPubMedGoogle Scholar
  • 35 Esposito K, Marfella R, Ciotola M, Palo C Di, Giugliano F, Giugliano G, DÁrmiento M, DÁndrea F, Giugliano D. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men.  JAMA. 2004;  292 1440-1446
    CrossrefPubMedGoogle Scholar
  • 36 Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells.  Proc Natl Acad Sci USA. 2003;  100 125-130
    CrossrefPubMedGoogle Scholar
  • 37 Weitzmann MN, Pacifici R. Estrogen regulation of immune cell bone interactions.  Ann N Y Acad Sci. 2006;  1068 256-274
    CrossrefPubMedGoogle Scholar
  • 38 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.  Nature. 1998;  391 82-86
    CrossrefPubMedGoogle Scholar
  • 39 Fajas L, Debril MB, Auwerx J. PPAR gamma: an essential role in metabolic control.  Nutr Metab Cardiovasc Dis. 2001;  11 64-69
    PubMedGoogle Scholar
  • 40 Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Rettig A, Renn W, Haring HU. The silent PPAR gamma exon 6 CAC (His) >CAT (His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany.  Exp Clin Endocrinol Diabetes. 2000;  108 341-346
    Article in Thieme ConnectPubMedGoogle Scholar

Correspondence

Prof. Dr. D. Muller-WielandMD 

I. Medizinischen Klinik für Allgemeine Innere Medizin der Asklepios Klinik St. Georg

Lohmühlenstraße 5

20099 Hamburg

Germany

Phone: +40/1818/85 30 24

Fax: +40/1818/85 30 29

Email: dirk.mueller-Wieland@ak-stgeorg.lbk-hh.de

      >